Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-25-044298
Filing Date
2025-05-15
Accepted
2025-05-15 16:36:46
Documents
70
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0241855-10q_aditxt.htm   iXBRL 10-Q 1303108
2 CERTIFICATION ea024185501ex31-1_aditxt.htm EX-31.1 10908
3 CERTIFICATION ea024185501ex31-2_aditxt.htm EX-31.2 10919
4 CERTIFICATION ea024185501ex32-1_aditxt.htm EX-32.1 5125
  Complete submission text file 0001213900-25-044298.txt   9058969

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE adtx-20250331.xsd EX-101.SCH 79936
6 XBRL CALCULATION FILE adtx-20250331_cal.xml EX-101.CAL 40110
7 XBRL DEFINITION FILE adtx-20250331_def.xml EX-101.DEF 411427
8 XBRL LABEL FILE adtx-20250331_lab.xml EX-101.LAB 720960
9 XBRL PRESENTATION FILE adtx-20250331_pre.xml EX-101.PRE 431119
72 EXTRACTED XBRL INSTANCE DOCUMENT ea0241855-10q_aditxt_htm.xml XML 987151
Mailing Address 737 N. FIFTH STREET, SUITE 200 RICHMOND VA 23219
Business Address 737 N. FIFTH STREET, SUITE 200 RICHMOND VA 23219 909-488-0844
Aditxt, Inc. (Filer) CIK: 0001726711 (see all company filings)

EIN.: 823204328 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39336 | Film No.: 25954389
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)